NEW YORK (GenomeWeb) – Mars Petcare said this week that it has acquired OptiGen, a DNA diagnostics company specializing in canine inherited disorders, for an undisclosed amount. Included in the acquisition are exclusive licenses to a portfolio of genetic disease tests patented in the US, Australia, and many countries in Europe, and an extensive biobank of more than 150,000 samples collected over 20 years representing various canine eye diseases. Moving forward these samples will be used to discover new genetic health markers for dogs, Mars Petcare said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.